Efficacy and Safety of SBRT Plus Gemcitabine, Cisplatin, and Sintilimab as First-Line Treatment for Unresectable Biliary Tract Cancer

NCT07638501 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

123

Enrollment

OTHER

Sponsor class

Conditions

Biliary Tract Cancer (BTC)

Interventions

DRUG: Sintilimab + GC
RADIATION: SBRT 7Gy✖️5 QD

Sponsor

Eastern Hepatobiliary Surgery Hospital